NBTI

A family of first-in-class anti-infectious drugs targeting Gram-negative infections

Gram-negative bacteria, a very serious threat

Gram-negative bacteria (e.g. Salmonella) pose a serious threat to global public health because they acquire resistance to antibiotics more rapidly than Gram-positive bacteria. However, there are very few registered or developing antibiotics that can target this type of bacteria. Their prevalence increases with the aging of the population, with the elderly being particularly vulnerable.

NBTI: A family of first-in-class anti-infectious drugs targeting Gram-negative infections

DEINOVE signed in March 2018 an exclusive license option agreement with the UK company REDX PHARMA for the NTBI program. DEINOVE has 9 months to confirm its interest for this series of molecules and exercise the option.

 

✓ A potential new class of active antibiotics against Gram-negative bacteria

The Novel Bacterial Topoisomerase Inhibitor (NBTI) program focuses on a new class of antibiotics targeting bacterial topoisomerase type II, an enzyme that controls the structure of DNA.

The main interest lies in focusing on a known target (that impacted by fluoroquinolones), but at a different site of action, which protects against cross-resistance. This approach targets multi-resistant Gram-negative bacteria such as Acinetobacter baumannii and Pseudomonas aeruginosa, bacteria on the list of the 12 most dangerous pathogens for human health published by WHO in 2017. They are particularly responsible for diseases such as nosocomial pneumonia (contracted at the hospital), which affects 750 000 patients a year in Europe and the United States, and for which nearly 12% of associated pathogens are multi-resistant to antibiotics.

✓ Currently in evaluation and lead optimization

The NTBI program has been the subject of prior optimization and in vivo evaluation by the REDX PHARMA scientific teams, confirming its efficacy potential. DEINOVE continues the work of selection and optimization (especially in terms of pharmacokinetic profile) for a possible entry of one or more molecules into the regulatory preclinical phase.

✓ Rapid bactericidal activity demonstrated in vitro (lead DNV08106)